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Abstract: 
While manganese (Mn) is essential for proper central nervous system (CNS) development, 
excessive Mn exposure may lead to neurotoxicity. Mn preferentially accumulates in the basal 
ganglia, and in adults it may cause Parkinson’s disease–like disorder. Compared to adults, 
younger individuals accumulate greater Mn levels in the CNS and are more vulnerable to its 
toxicity. Moreover, the mechanisms mediating developmental Mn-induced neurotoxicity are not 
completely understood. The present study investigated the developmental neurotoxicity elicited 
by Mn exposure (5, 10 and 20 mg/kg; i.p.) from postnatal day 8 to PN27 in rats. Neurochemical 
analyses were carried out on PN29, with a particular focus on striatal alterations in intracellular 
signaling pathways (MAPKs, Akt and DARPP-32), oxidative stress generation and cell death. 
Motor alterations were evaluated later in life at 3, 4 or 5 weeks of age. Mn exposure (20 mg/kg) 
increased p38MAPK and Akt phosphorylation, but decreased DARPP-32-Thr-34 
phosphorylation. Mn (10 and 20 mg/kg) increased caspase activity and F2-isoprostane 
production (a biological marker of lipid peroxidation). Paralleling the changes in striatal 
biochemical parameters, Mn (20 mg/kg) also caused motor impairment, evidenced by increased 
falling latency in the rotarod test, decreased distance traveled and motor speed in the open-field 
test. Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in 
p38MAPK phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F2-
isoprostane production. Trolox™ also reversed the Mn-induced motor coordination deficits. 
These findings are the first to show that long-term exposure to Mn during a critical period of 
neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative 
stress markers, p38MAPK phosphorylation and caspase activity in the striatum. Moreover, we 
establish Trolox™ as a potential neuroprotective agent given its efficacy in reversing the Mn-
induced neurodevelopmental effects. 
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Article: 
Introduction 
 
Manganese (Mn) is an essential ubiquitous trace element required for normal growth, 
development and cellular homeostasis (Aschner and Aschner 2005; Aschner et al. 2007). Both in 
humans and in animals, Mn acts as an essential cofactor of several enzymes required for 
neuronal and glial cell function, as well as enzymes involved in neurotransmitter synthesis and 
metabolism (Aschner and Aschner 2005; Aschner et al. 2007). Despite its indispensable role in 
multiple metabolic functions, excessive Mn exposure may lead to increased metal accumulation 
in the brain and neurotoxicity in the basal ganglia, particularly globus pallidus, striatum and 
substantia nigra pars reticulata (Bowman et al. 2011; Dobson et al. 2004; Perl and Olanow 2007; 
Yamada et al. 1986). Increased brain Mn levels may cause a clinical disorder referred to as 
manganism, which is characterized by extrapyramidal symptoms resembling idiopathic 
Parkinson’s disease (Menezes-Filho et al. 2009; Roth 2009). Moreover, Mn neurotoxicity has 
been linked to the development of neurodegenerative diseases, such as Alzheimer’s disease, 
amyotrophic lateral sclerosis (Eschenko et al. 2010) and prion disease (Bowman et al. 2011). 
Despite the numerous studies on the neurotoxicity of Mn in adults, little is known about its 
effects on the developing central nervous system (CNS), which is the most susceptible period to 
toxic insult (Bondy and Campbell 2005; Grandjean and Landrigan 2006; Rodier 1995; Zheng et 
al. 2003). Furthermore, several lines of research suggest that developmental exposure to Mn may 
predispose individuals to later-life neurological disorders (Erikson et al. 2007; Hafeman et al. 
2007; Moreno et al. 2009a, b). Notably, newborns retain greater Mn levels than adults (Hafeman 
et al. 2007), likely due to inefficient excretion, low physiological Fe levels as well as a 
permeable blood–brain barrier (Roth 2009), or an increased requirement for Mn immediately 
after birth. 
Mn exposure is inherent to environmental and occupational conditions, given its ubiquitous use 
in water treatment, manufacturing of dry batteries, gasoline additives (as an antiknock agent; 
methylcyclopentadienyl manganese tricarbonyl, MMT) and fungicides (Burton and Guilarte 
2009; Eschenko et al. 2010; Santamaria 2008). Moreover, Mn exposure may also result from 
administration of parenteral nutrition, where excessive Mn supplementation may predispose 
primarily children to neurological disorders (Erikson et al. 2007; Hardy 2009; Suzuki et al. 
2003). 
The late fetal and neonatal periods are characterized by significant changes in brain structure and 
function as well as cellular and intercellular signaling (Tkac et al. 2003). Substantial acceleration 
of RNA, DNA and protein synthesis, neuronal migration, growth of glial cells (particularly of 
astroglia, the main site for glutamate and metal uptake) and myelination of axons continue 
during the postnatal period (Gottlieb et al. 1977; Rice and Barone 2000; Rodier 1995). The rat 
brain between postnatal days 7 and 28 (PN7–28) represents an established model for studies on 
human brain development. From a neurodevelopmental point of view, the rat PN7 corresponds 
approximately to human gestational week 34, while rat PN28 corresponds to a child between 2 
and 3 years of age (Dobbing 1990). Additionally, the preweaning and early postweaning periods 
coincide with the development of dopaminergic pathways in brain regions such as the prefrontal 
cortex, nucleus accumbens and striatum, which are critical in regulating behavioral executive 
functions associated with learning, memory and attention, as well as motor functions (Broaddus 
and Bennett 1990a, b; Leo et al. 2003; Lozoff and Georgieff 2006; Packard and Knowlton 2002). 
Given the sensitivity of dopaminergic systems to Mn, early exposure to this metal may result in 
significant neurological deficits in developing brain structures (Cordova et al. 2012; Kern et al. 
2010). 
The mechanisms that mediate Mn-induced neurotoxicity are not fully understood, but seem to be 
associated with mitochondrial dysfunction, leading to cell death via the formation of reactive 
oxygen species (ROS) and oxidative stress (Gunter et al. 2006; Roth and Garrick 2003; Tamm et 
al. 2008; Zhang et al. 2008). Higher rates of striatal oxidative stress have been noted in 
developmentally induced Mn toxicity (Avila et al. 2008; Erikson et al. 2007). Furthermore, an 
association linking oxidative stress in the striatum with impairment in motor activity has been 
described (de Oliveira et al. 2007). 
Specific signaling pathways coupled with programmed cell death are activated upon in vitro Mn 
exposure, including protein kinase C, caspases and the mitogen-activated protein kinases, such as 
c-Jun amino-terminal kinase (JNK), extracellular regulated protein kinase (ERK) and p38MAPK 
(Cai et al. 2011; Crittenden and Filipov 2011; Hirata et al. 2004; Ito et al. 2006; Jang 2009; 
Latchoumycandane et al. 2005; Park and Park 2010; Shin et al. 2010). While mostly derived 
from in vitro studies, recently, we have demonstrated the effects of short-term Mn exposure 
(PN8–12) on the modulation of ERK1/2, Akt, as well as dopamine and cAMP-regulated 
phosphoprotein of 32kD (DARPP-32) phosphorylation in the striatum of immature rats (Cordova 
et al. 2012). Although all these pathways might be involved in the regulation of gene expression, 
embryogenesis, cell proliferation and migration, cell death/survival and neuroplasticity (Hanada 
et al. 2004; Svenningsson et al. 2004; Thomas and Huganir 2004), data regarding the modulation 
of such signaling pathways in response to prolonged Mn exposure during the early postnatal 
period have yet to be defined. 
The biological consequences of developmental Mn exposure may be severe and possibly with 
late onset, affecting neurogenesis, learning and memory. Furthermore, these early effects may 
predispose individuals to neurodegenerative disorders that unmask only decades later in life. We 
have recently demonstrated that developmental exposure of immature rats to Mn for a short 
period (5 days; from PN8 to 12) caused marked motor deficits and altered intracellular signaling 
pathways associated with regulation of proliferation, plasticity and cell death (Cordova et al. 
2012) in a manner that might be partially dependent on oxidative stress. The relationship 
between these signaling pathways and more protracted Mn exposure during the early postnatal 
period has yet to be defined. Accordingly, the present study was carried out to evaluate 
alterations in striatal cell signaling pathways, production of cell death, induction of oxidative 
stress and motor deficits in a model of long-term developmental Mn exposure (20 days, from 
PN8 to 27). Moreover, the role of a chain-breaking antioxidant (Trolox™) in modulating the 
effects of Mn on these biochemical and behavioral parameters and its neuroprotective efficacy 
against Mn-induced neurotoxicity were also evaluated. 
Methods 
 
Reagents 
 
The primary antibodies anti-ERK1/2, anti-p38MAPK, anti-JNK1/2 and manganese chloride 
(MnCl2) were obtained from Sigma (St. Louis, MO, USA). The anti-phospho-CREB, anti-
CREB, anti-phospho-ERK1/2, anti-phospho-p38MAPK, anti-phospho-JNK1/2/3, anti-Akt, anti-
phospho-Akt, anti-DARPP-32, anti-phospho-DARPP-32-Thr-34 and anti-phospho-DARPP-32-
Thr-75 antibodies were purchased from Cell Signaling (Beverly, MA, USA). Anti-β-actin was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Acrylamide, bis-acrylamide, 
β-mercaptoethanol, Hybond™ nitrocellulose, Hyperfilm™ ECL, sodium dodecyl sulfate (SDS), 
Tris, secondary antibody (anti-rabbit IgG-horseradish peroxidase-conjugated) and ECL™ 
detection reagents were obtained from GE Healthcare Life Sciences (Piscataway, NJ, USA). 6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox™) was obtained from 
Calbiochem (La Jolla, CA, USA). The N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin 
(DEVD-AMC) was obtained from Biomol (Plymouth Meeting, PA, USA). All other reagents 
were of the highest analytical grade. 
Animals and treatments 
 
Wistar rats of both genders were obtained from the Federal University of Santa Catarina 
breeding colony. The animals were maintained in an air-conditioned room (22 ± 1 °C) on a 12-h 
light/dark cycle with water and food available ad libitum. They were treated, manipulated and 
euthanized according to the “Principles of Laboratory Animal Care” (NIH publication no. 80-23, 
revised 1996) and approved by the Committee on the Ethics of Animal Experiments of the 
Federal University of Santa Catarina (CEUA/UFSC; www.ceua.ufsc.br; Permit Number: 
PP00345). All efforts were made to minimize the number of animals used and animal suffering. 
At birth, the number of pups was randomly culled to eight pups per litter. The treatments began 
when the pups were 8 days old (PN8). The litters were randomly assigned to each treatment 
group, and the treatments were carried out at the same time every day (2:00 PM). 
For the Mn exposure protocol, four to twelve groups from different litter were used. Each group 
with eight pups (8 days old) of both sexes was divided into four treatments (control and MnCl2 
5, 10 or 20 mg/kg) with two animals in each treatment group. The pups were treated for 20 
consecutive days (8th to 27th postnatal day; PN8–27) with one daily intraperitoneal (i.p.) 
injection of saline (NaCl, 0.9 %; control) or MnCl2 (5, 10 or 20 mg/kg, diluted in saline), as 
previously described (Cordova et al. 2004, 2012; Rocha et al. 1995). The dosing regimen was 
chosen in an attempt to mimic Mn exposures derived from total parenteral nutrition (TPN), 
which have been associated with significant increases in brain Mn levels both in adults and in 
children (Ejima et al. 1992; Fell et al. 1996). The highest Mn dose used herein (20 mg/kg) leads 
to an analogous increase in striatal Mn levels as observed in pediatric patients receiving TPN 
(Chaki et al. 2000; Ono et al. 1995). Rats were euthanized on the 29th postnatal day (PN29) by 
decapitation, and the structures of interest were dissected out for neurochemical analyses 
(Cordova et al. 2004, 2012). Briefly, the brain was carefully removed, the cerebral hemispheres 
were divided, and the hippocampi were isolated using two fine brushes (Cordova et al. 2012; 
Rodnight and Leal 1990). This procedure was followed by displacement of the cortex and 
striatum. The striatum was carefully dissected out and separated from nearby structures with a 
sharp spatula. 
In addition, pups were treated concomitantly with Mn and the antioxidant 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox™) to determine neuroprotective efficacy of this 
compound against Mn-induced neurotoxicity. The same protocol as previously described was 
carried out with two pups in each treatment group: saline (0.9 % NaCl; control), Trolox™ 1 
mg/kg, MnCl2 20 mg/kg, MnCl2 20 mg/kg plus Trolox™ 1 mg/kg (administered 10 min before 
Mn) (Cordova et al. 2012). The pups’ body weights were measured daily from PN8 to 29, and 
the weight gain (g) is reported as mean ± S.E.M. 
Brain metal analyses 
 
Tissue concentrations of Mn and iron (Fe) were analyzed by atomic absorption spectroscopy 
(Varian AA240™, Varian Inc., Palo Alto, CA, USA) (Fitsanakis et al. 2008). The striatum, 
hippocampus and cerebral cortex were digested in ultrapure nitric acid (1:10 wt/vol dilution) for 
48–72 h in a sand bath (60 °C). One hundred microliters of digested tissue was brought to 1 ml 
of total volume with 2 % nitric acid and analyzed for Mn and Fe content. The mixture was then 
centrifuged, and the clear supernatant was used for analysis (100-μl aliquot brought up to a 1 ml 
volume with 2 % nitric acid). Bovine liver (10 μg Mn/l) was digested in ultrapure nitric acid and 
used as an internal standard for analysis. The data are expressed as μg Mn or Fe/g tissue (mean ± 
S.E.M.). 
Western blotting 
 
The brain area of interest (striatum) was dissected and mechanically homogenized in 500 μl of 
sample buffer (200 mM Tris, 40 mM EDTA, 4 % SDS, pH 6,8), and the homogenates were 
immediately boiled for 5 min. Sample dilution solution (1:4 vol/vol; 40 % glycerol, 50 mM Tris 
and minimal bromophenol blue) and β-mercaptoethanol were added to each sample at a final 
concentration of 5 %. Protein concentrations were estimated by the method described in Peterson 
(1977) based on a standard curve with bovine serum albumin. The samples (60 μg of total 
protein/lane) were separated by SDS–PAGE (miniVE Vertical Electrophoresis System™, GE 
Healthcare Life Sciences, Piscataway, NJ, USA) using 10 % gels (Cordova et al. 2004, 2012). 
The proteins were transferred to nitrocellulose membrane using a semi-dry blotting apparatus 
(TE 70 SemiPhor™ Unit, GE Healthcare Life Sciences, Piscataway, NJ, USA) (1.2 mA/cm2; 1.5 
h) as described by Bjerrum and Heegaard (1988). The membranes were blocked (1 h) with 5 % 
skim milk in TBS (10 mM Tris, 150 mM NaCl, pH 7.5). ERK1/2, JNKs (46 and 54 kDa), 
p38MAPK, Akt, CREB and DARPP-32 (total and phosphorylated forms) were detected with 
specific antibodies, diluted in TBS-T (10 mM Tris, 150 mM NaCl, 0,1 % Tween-20, pH 7.5) 
containing 2.5 % BSA, after overnight incubation. Final primary antibody dilutions were 1:1,000 
(anti-phospho-CREB, anti-CREB, anti-Akt, anti-phospho-Akt-Ser-473, anti-DARPP-32, anti-
phospho-DARPP-32-Thr-34, anti-phospho-DARPP-32-Thr-75, anti-phospho-JNK1/2/3 and anti-
phospho-p38MAPK), 1:2,000 (anti-phospho-ERK1/2 and anti-β-actin), 1:10,000 (anti-JNK1/2 
and anti-p38MAPK) or 1:40,000 (anti-ERK1/2). Next, the membranes were incubated for 1 h 
with anti-rabbit peroxidase-linked secondary antibody (1:4,000) and the reactions developed by 
chemiluminescence. All steps (blocking and antibody incubations) were followed by three 
washes (5 min) of the membranes with TBS-T. The optical density (OD) of the bands was 
quantified with Scion Image™ (Frederick, MD, USA). The phosphorylation level of each protein 
was determined as a ratio of the OD of the phosphorylated band to OD of the total band. The 
data are expressed as percentage of the control (considered as 100 %). Values are presented as 
mean ± S.E.M (Posser et al. 2007). 
Quantitation of F2-IsoPs 
 
The F2-isoprostanes (F2-IsoPs) are considered reliable biomarkers of oxidative stress 
(particularly lipid peroxidation) in both in vitro and in vivo models (Milatovic et al. 2009). Total 
F2-IsoPs were determined with a stable isotope dilution method with detection by gas 
chromatography/mass spectrometry and selective ion monitoring as previously described 
(Milatovic et al. 2007; Morrow and Roberts 1999). Total F2-IsoPs were measured in the striatum 
dissected from the animals exposed in vivo to different doses of Mn and stored at −80 °C until 
analysis. Briefly, the striata were homogenized in Folch solution and lipids extracted from 
chloroform layer by evaporation (Milatovic and Aschner 2009) and then subjected to chemical 
saponification using 15 % KOH to hydrolyze bound F2-IsoPs. The homogenates were adjusted 
to a pH of 3, followed by the addition of 0.1 ng of 15-F2α-IsoP-d4 internal standard. F2-IsoPs 
were subsequently purified by C18 and silica Sep-Pak extraction and by thin-layer 
chromatography. They were then analyzed by pentafluorobenzyl ester, a trimethylsilyl ether 
derivative, via gas chromatography, negative ion chemical ionization-mass spectrometry. 
Caspase activity 
 
Caspase activity was monitored fluorimetrically by the production of fluorescent 7-amino-4-
methylcoumarin (AMC) from DEVD-AMC fluorogenic substrate for caspase-3 and related 
cysteine proteases. Striatal homogenates were prepared (1:5, w/v) in a buffer containing 10 mM 
HEPES pH 7.4, 42 mM KCl, 5 mM MgCl2, 1 mM phenylmethylsulfonylfluoride, 0.1 mM 
EDTA, 0.1 mM EGTA, 1 μg/ml pepstatin A, 1 μg/ml leupeptin, 5 μg/ml aprotinin, 0.5 % 3-[(3-
cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate (CHAPS) and 1 mM dithiothreitol 
(DTT) at 4 °C. The reaction was carried out by mixing this homogenate (0.1 mg protein) with a 
buffer containing 25 mM HEPES pH 7.4, 0.1 % CHAPS, 1 mM EDTA, 10 % sucrose and 3 mM 
DTT. The reaction was started by the addition of 10 μM caspase-3 fluorogenic substrate DEVD-
AMC. Cleavage of the fluorogenic substrate was detected spectrofluorimetrically (Perkin Elmer 
LS55, Boston, MA, USA) after 2 h of incubation at 37 °C, using excitation and emission 
wavelengths of 380 and 460 nm, respectively (Zuse et al. 2007). Fluorescence of blank samples 
containing no fluorogenic substrate was subtracted from these values. Protein content was 
determined by Lowry’s method (Lowry et al. 1951), and the caspase activity was expressed as 
mean percent of control (100 %) ± S.E.M. 
Behavioral tests 
 
The animals were kept until PN37. All animals were tested at 22, 29 and 36 days of age (3, 4 and 
5 weeks old) on a rotarod and on PN37 on an open-field task (Cordova et al. 2012). Animals 
were habituated to the test room for 1 h prior to the initiation of the behavior tests, which were 
carried out during the light phase of the cycle (10:00–17:00 h). 
Rotarod analyses 
 
The Rota-Rod system (Insight Equipamentos Científicos, Ribeirão Preto, Brazil) for locomotor 
assessment measures the time period an animal maintains its balance on a moving cylinder 
(Aguiar et al. 2009). Animals were first conditioned on a stationary rod for 30 s, and during this 
time, animals that fell off the cylinder were placed back on the rotarod. Next, the animals were 
conditioned at a constant speed of 5 rpm for a period of 90 s. Animals that failed the first 
conditioning were allowed two additional conditioning periods, and those that failed the third 
conditioning period were omitted from further testing. This assured that all the animals in all the 
treatment groups attained an analogous baseline (data not shown). 
The same basic conditioning methodology was employed in testing treatment and control groups. 
Thirty minutes after the last conditioning, each animal was placed on the rotarod and its latency 
for falling determined. The starting speed was 5 rpm, and it was increased by 0.1 revolutions per 
second. 
Open-field analyses 
 
To evaluate Mn-induced motor changes, the animals were tested in the circular open field 
(Aguiar et al. 2009). The apparatus consists of acrylic chamber with 50 cm height × 60 cm 
diameter (Insight Equipamentos Científicos, Ribeirão Preto, Brazil) and is placed in a room with 
a ceiling-mounted video camera. Each animal was placed in the apparatus for 10 min, and the 
distance, average speed, number of rearing and grooming were recorded. The data were 
evaluated with behavioral analysis software, ANY-maze™ (Stoelting, Wood Dale, IL, USA). 
Statistical analyses 
 
Data are expressed as mean ± S.E.M, and statistical significance was assessed by one-way 
analysis of variance (ANOVA) followed by Duncan’s post hoc test when appropriate, except for 
the rotarod test that does not display a Gaussian distribution. Therefore, for this analysis the 
nonparametric Kruskal–Wallis test followed by Dunn’s post hoc was applied. Analyses were 
performed with STATISTICA™ 5.1’98 Edition (StatSoft, Tulsa, OK, USA). p ≤ 0.05 was 
considered to be statistically significant. 
Results 
 
Brain metal accumulation 
 
Brain Mn and Fe concentrations were analyzed in rats developmentally exposed to Mn for 20 
days. Striatal Mn levels significantly increased, approximately fivefold in the 10 mg Mn/kg (p < 
0.01) group and seven times in the 20 mg Mn/kg (p < 0.001) group (Fig. 1a) relative to controls. 
Moreover, a significant increase in Mn levels was also observed in the hippocampus (p < 0.01 in 
the 10 mg Mn/kg group; p < 0.001 in the 20 mg Mn/kg group; Fig. 1a) and cerebral cortex (p < 
0.01 in the 10 mg Mn/kg group; p < 0.001 in the 20 mg Mn/kg group; Fig. 1a). Fe levels 
significantly increased (20 and 35 %) only in the striatum of animals treated with 10 or 20 mg 
Mn/kg, respectively (p < 0.001; Fig. 1b). At the termination of the study (PN29), no differences 
were noted in weight gain (Table 1) for any of the groups when compared with controls. 
 
Fig. 1 
Effects of Mn exposure on metal accumulation in the hippocampus, striatum and cerebral cortex 
of immature rats. The panels show the accumulation of Mn (a) and Fe (b). Rat pups were treated 
with saline (control; NaCl 0.9 %) or MnCl2 at doses of 5, 10 or 20 mg/kg for 20 days (PN8–27), 
and the brain metal concentrations were analyzed on PN29. Results represent mean ± S.E.M and 
are expressed in μg metal/g tissue. Statistical analysis was performed by ANOVA followed by 
Duncan’s test. n = 4; * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control 
Table 1 
Weight gain in rats developmentally exposed to Mn 
  Body weight PN8 (g) Body weight PN29 (g) Weight gain (g) 
Control 13.20 ± 0.78 61.88 ± 2.21 49.81 ± 1.52 
5 mg Mn/kg 14.51 ± 0.96 65.16 ± 1.91 50.65 ± 1.38 
10 mg Mn/kg 13.39 ± 0.73 62.58 ± 1.78 49.18 ± 1.21 
20 mg Mn/kg 13.90 ± 0.70 58.54 ± 2.08 46.26 ± 1.18 
Immature rats were treated with saline (control; NaCl 0.9 %) or MnCl2 at doses of 5, 10 or 20 
mg/kg for 20 days (PN8–27). The animals’ body weights were recorded on PN8 and 29. Results 
represent mean ± S.E.M and are expressed in grams (g). Statistical analysis was performed by 
ANOVA; n = 15 
Since the striatum is an important target for Mn neurotoxicity (Avila et al. 2008; Bowman et al. 
2011; Cordova et al. 2012; Erikson et al. 2007), next we performed neurochemical analyses in 
this structure. 
Effects of Mn exposure on signaling pathways 
 
Phosphorylation and expression of MAPKs, Akt, CREB and DARPP-32 were evaluated on 
PN29 in the striatum of rats exposed to Mn from PN8 to 27. The phosphorylation of p38MAPK 
(Fig. 2a) was increased in the 10 (21.25 ± 6.05 %, p < 0.01) and 20 mg/kg (33.31 ± 8.14 %, p < 
0.001) treatment groups. Akt phosphorylation (Fig. 2b) was also significantly increased in the 20 
mg/kg group (14.92 ± 2.94 %, p < 0.001). Conversely, DARPP-32-Thr-34 phosphorylation (Fig. 
2c) was significantly decreased in the 20 mg/kg Mn group (11.05 ± 2.34 %, p < 0.01). The 
phosphorylation and/or expression of ERK1/2, JNK1/2/3 (p54 and p46) and CREB (Fig. 2d) was 
indistinguishable from controls upon exposures to Mn. 
 
Fig. 2 
Effects of in vivo Mn exposure for 20 days on the phosphorylation of MAPK, AKT, CREB and 
DARPP-32 in the striatum of immature rats. The panels show representative immunoblots and 
quantification of phosphorylation of p38MAPK (a), AKT (b), DARPP-32-Thr-34 and DARPP-
32-Thr-75 (c), ERK1/2, JNKs (p46 and p54), CREB and β-actin (d) in striata of rats treated with 
saline (control; NaCl 0.9 %) or MnCl2 at doses of 5, 10 or 20 mg/kg/day (PN8–27). The 
structures were analyzed on PN29. The total and phosphorylated form of each protein was 
detected with specific antibodies, and the reaction was developed by chemiluminescence. The 
phosphorylation level of each protein was determined as the ratio of OD of the phosphorylated 
band to OD of the total band, and the data are expressed as percentage of the control (considered 
as 100 %). Values are presented as mean ± S.E.M. Statistical analysis was performed by 
ANOVA followed by Duncan’s test. n = 12; ** p < 0.01, *** p < 0.001 compared to control 
Mn exposure may alter signaling pathways associated with cell death and cell survival. 
Accordingly, next we analyzed the enzymatic activity of caspase-3/7, which plays a key role in 
apoptosis. The analysis was carried out with DEVD cleavage fluorescent test in the striata of 
immature rats exposed to Mn for 20 days. As shown in Fig. 3, Mn significantly increased (p < 
0.001) caspase activity both in the 10 mg/kg (30.10 ± 6.23 %) and in the 20 mg/kg (29.17 ± 6.51 
%) treatment groups compared with the controls. 
 
Fig. 3 
Caspase activity measured by the DEVD cleavage test in the striata of immature rats exposed in 
vivo to Mn for 20 days (PN8–27). The panel shows the DEVD cleavage test from rats treated 
with saline (control; NaCl 0.9 %) or MnCl2 at doses of 5, 10 or 20 mg/kg/day (PN8–27) and the 
structures analyzed at PN29. Results represent mean ± S.E.M and are expressed as percentage of 
control (100 %). Statistical analysis was performed by ANOVA followed by Duncan’s test. n = 
8; *** p < 0.001 compared to control 
Oxidative stress in Mn neurotoxicity 
 
Recently, we demonstrated increased brain F2-IsoPs generation in a short-term model of Mn 
exposure (Cordova et al. 2012). Here, we also evaluated F2-IsoPs generation in rat striata upon a 
more protracted exposure to this metal. Consistent with our previous results, exposure to Mn at 
all doses led to a significant increase (p < 0.001; Fig. 4) in F2-IsoPs generation in the striata of 
developing rats. 
 
Fig. 4 
F2-IsoPs production in the striata of immature rats exposed in vivo to Mn for 20 days (PN8–27). 
The panel shows F2-IsoPs production in rats treated with saline (control; NaCl 0.9 %) or MnCl2 
at doses of 5, 10 or 20 mg/kg/day (PN8–27). Striata were analyzed on PN29. Results represent 
mean ± S.E.M and are expressed as ng F2-IsoPs/g tissue. Statistical analysis was performed by 
ANOVA followed by Duncan’s test. n = 4; *** p < 0.001 compared to control 
Effects of Mn exposure on motor activity 
 
As shown in Fig. 5, overall performance on the rotarod test was indistinguishable between 
controls and rats treated with 5 or 10 mg Mn/kg. However, animals treated with 20 mg Mn/kg 
showed a significant decrease (p < 0.05) in the overall latency for falling off the rotarod versus 
controls. 
 
Fig. 5 
Motor coordination in rats exposed in vivo to Mn. Control and treated rats were tested on 22, 29 
and 36 days of age (3, 4 and 5 weeks old) on the rotarod task. The graphic shows the overall 
latency for falling in rats treated (PN8–27) with saline (control; NaCl 0.9 %) or MnCl2 at doses 
of 5, 10 or 20 mg/kg/day. Results represent median ± interquartile range and are expressed in 
seconds (s) to latency for falling derived from twelve independent experiments. Statistical 
analysis was performed by Kruskal–Wallis followed by Dunn’s post hoc test. * p < 0.05 
compared to control 
Protective effects of Trolox™ on Mn-induced neurotoxicity 
 
In order to gain a better understanding on the role of oxidative stress in mediating Mn-induced 
neurotoxicity, we co-treated animals with the chain-breaking antioxidant Trolox™ (1 mg/kg) and 
Mn (20 mg/kg). As shown in Fig. 6a, Trolox™ fully reversed the effect of Mn on p38MAPK 
phosphorylation, to the levels indistinguishable from controls (p < 0.01). However, Trolox™ 
failed to block the Mn-induced increase in Akt phosphorylation (Fig. 6b). Interestingly, Trolox™ 
per se also increased Akt phosphorylation (35.55 ± 10.92 %, p < 0.05; Fig. 6b). Furthermore, 
Trolox™ reversed the Mn-induced increase in caspase activity to the levels indistinguishable 
from controls (p < 0.05 relative to Mn alone, Fig. 7) and decreased Mn-mediated F2-IsoPs 
production (p < 0.001 relative to Mn alone; Fig. 8). No changes in the rats’ weight were noted 
upon Trolox™ treatment (Table 2). Finally, as shown in Fig. 9, co-treatment with Mn and 
Trolox™ caused a significant (p < 0.05) improvement in motor coordination compared to Mn-
treated animals. 
 
Fig. 6 
Effects of in vivo exposure to Mn and/or Trolox™ for 20 days (PN8–27) on phosphorylation of 
p38MAPK (a) and Akt (b) in the striatum of immature rats. The panels show representative 
immunoblots and quantification of p38MAPK and Akt phosphorylation from rats treated with 
saline (control; NaCl 0.9 %), MnCl2 20 mg/kg (Mn), Trolox™ 1 mg/kg (Tr) or MnCl2 20 mg/kg 
plus Trolox™ 1 mg/kg (Mn + Tr) for 20 days (PN8–27). The structures were analyzed on PN29. 
The total and phosphorylated form of each protein was detected with specific antibodies, and the 
reaction was developed by chemiluminescence. The phosphorylation level of each protein was 
determined as a ratio of OD of the phosphorylated band to OD of the total band, and the data are 
expressed as percentage of the control (considered as 100 %), and the values are presented as 
mean ± S.E.M. Statistical analysis was performed by ANOVA followed by Duncan’s test. n = 
12; * p < 0.05, ** p < 0.01, compared to control; ## p < 0.01 compared to 20 mg Mn/kg group 
 
Fig. 7 
Effects of Trolox™ on caspase activity measured by DEVD cleavage test in striata from 
immature rats exposed in vivo to Mn for 20 days (PN8–27). The panel shows the DEVD 
cleavage test from rats treated with saline (control; NaCl 0.9 %), MnCl2 20 mg/kg (Mn), 
Trolox™ 1 mg/kg (Tr) or MnCl2 20 mg/kg plus Trolox™ 1 mg/kg (Mn + Tr) for 20 days (PN8–
27). The structures were analyzed on PN29. Results represent mean ± S.E.M and are expressed 
as percentage of control (100 %). Statistical analysis was performed by ANOVA followed by 
Duncan’s test. n = 8; *** p < 0.001 compared to control; # p < 0.05 compared to 20 mg Mn/kg 
group. 
 
Fig. 8 
F2-IsoPs production in striata from immature rats exposed in vivo to Mn and/or Trolox™ for 20 
days (PN8–27). The panel shows F2-IsoPs production from rats treated with saline (control; 
NaCl 0.9 %), MnCl2 20 mg/kg (Mn), Trolox™ 1 mg/kg (Tr) or MnCl2 20 mg/kg plus Trolox™ 
1 mg/kg (Mn + Tr) for 20 days (PN8–27). The structures were analyzed on PN29. Results 
represent mean ± S.E.M and are expressed as ng F2-IsoPs/g tissue. Statistical analysis was 
performed by ANOVA followed by Duncan’s test. n = 4; ** p < 0.01 compared to control; ### p 
< 0.001 compared to 20 mg Mn/kg group 
Table 2 
Effects of Mn and/or Trolox™ on body weight gain in immature rats exposed in vivo 
  Body weight PN8 (g) Body weight PN29 (g) Weight gain (g) 
Control 13.79 ± 0.68 65.74 ± 2.91 51.94 ± 2.37 
Mn 13.19 ± 0.70 60.08 ± 2.59 46.89 ± 2.03 
Tr 14.08 ± 1.21 64.71 ± 3.85 50.64 ± 2.85 
Mn + Tr 14.02 ± 0.72 64.22 ± 2.68 50.20 ± 2.13 
 
Immature rats were treated with saline (control; NaCl 0.9 %), MnCl2 20 mg/kg (Mn), Trolox™ 1 
mg/kg (Tr) or MnCl2 20 mg/kg plus Trolox™ 1 mg/kg (Mn + Tr) for 20 days (PN8–27). The 
animals’ body weights were recorded on PN8 and PN29. Results represent mean ± S.E.M and 
are expressed in grams (g). Statistical analysis was performed by ANOVA; n = 8 
 
Fig. 9 
Effects of Trolox™ on motor coordination of immature rats exposed to Mn. Rats were treated for 
20 days (PN8–27) with saline (control; NaCl 0.9 %), MnCl2 20 mg/kg (Mn), Trolox™ 1 mg/kg 
(Tr) or MnCl2 20 mg/kg plus Trolox™ 1 mg/kg (Mn + Tr) and tested on 22, 29 and 36 days of 
age (3, 4 and 5 weeks old) on the rotarod task. The graphic shows the overall latency for falling, 
and results represent mean ± interquartile range and are expressed as seconds (s) to latency for 
falling derived from twelve independent experiments. Statistical analysis was performed by 
Kruskal–Wallis followed by Dunn’s post hoc test. * p < 0.05 compared to control., # p < 0.05 
compared to 20 mg Mn/kg group 
In the open-field test, animals treated with the highest Mn dose (20 mg/kg) showed a significant 
(p < 0.05) reduction in the distance traveled (Fig. 10a) and speed (Fig. 10b) versus controls. Co-
treatment with Trolox™ did not block the Mn-induced deficits (Fig. 10). Mn exposure did not 
alter grooming (Fig. 10c) or rearing (Fig. 10d) behaviors. 
 
Fig. 10 
Evaluation of motor changes induced by Mn and/or Trolox™ exposure of immature rats in the 
circular open-field task. Rats were treated with saline (control; NaCl 0.9 %), MnCl2 20 mg/kg 
(Mn), Trolox™ 1 mg/kg (Tr) or MnCl2 20 mg/kg plus Trolox™ 1 mg/kg (Mn + Tr) for 20 days 
(PN8–27). The panels show the distance (m) (a), speed (m/s) (b), grooming frequency (c) and 
rearing frequency (d). Results represent mean ± S.E.M. Statistical analysis was performed by 
ANOVA followed by Duncan’s test. n = 12; *p < 0.05 compared to control 
Discussion 
 
Mn is an essential metal for living organisms, but excessive levels may cause pathological 
processes characterized by irreversible CNS damage (Lazrishvili et al. 2009). The occupational 
exposure of adults to Mn represents a toxicological concern given its widespread use in 
manufacturing of dry batteries, gasoline additives and fungicides (Burton and Guilarte 2009; 
Eschenko et al. 2010; Santamaria 2008). In newborns and children, both breast milk (Ljung et al. 
2009; Yoon et al. 2011) and TPN (Fell et al. 1996) contribute to increased Mn body burden; 
however, from a toxicological viewpoint, TPN likely represents a more critical concern for 
exposure (Aschner and Aschner 2005). The exposure regimen used herein was chosen in an 
attempt to mimic Mn exposures in infants receiving TPN feeds. Our results established a 
sevenfold increase in striatal Mn levels in exposed rats (Fig. 1a). It is noteworthy that TPN in 
pediatric patients has also been shown to cause a sevenfold increase in blood and striatal Mn 
levels (Chaki et al. 2000; Ono et al. 1995). Accordingly, the present exposure protocol leads to 
striatal Mn levels that are likely inherent to TPN-fed children, particularly those with 
simultaneous liver failure disease (Fell et al. 1996). 
Given the dearth of information on Mn neurotoxicity in the developing brain, the present study 
addressed the potential for this metal to generate oxidative stress and alter intracellular signaling 
pathways and behavior in developing rats. Recently, we showed increased oxidative stress and 
modulation of ERK1/2, Akt and DARPP-32 in PN14 rats upon in vivo exposure to Mn (Cordova 
et al. 2012). However, given the importance of the second to fourth postnatal weeks in 
maintaining optimal neurodevelopment, here we tested the effects of protracted Mn exposure 
(PN8–29) to allow for better understanding of the molecular and behavioral effects of this metal 
on rat brain development. 
Consistent with earlier observations (Normandin et al. 2002; Roth 2009; Yamada et al. 1986), we 
noted increased Mn levels in the striatum of rats dosed with 10 and 20 mg Mn/kg (Fig. 1a). 
However, a significant increase in Mn levels was also noted in the hippocampus and cerebral 
cortex, corroborating previous studies showing the propensity of Mn to accumulate throughout 
the CNS, both in young and in adult animals (Dorman et al. 2000; Morello et al. 2008, 2009a; 
Normandin et al. 2002; Schneider et al. 2009). In addition, we observed a discrete increase in Fe 
levels in the striatum of PN29 animals treated with 10 and 20 mg Mn/kg (Fig. 1b), but not in 
animals treated with a lower dose (5 mg Mn/kg). Notably, increased Fe levels in the absence of 
significant changes in the level of other metals were previously observed in the striatum of 
juvenile mice exposed to Mn (Erikson et al. 2007; Hafeman et al. 2007; Moreno et al. 2009a, b). 
Therefore, it is possible that Mn exerts its effects on the immature striatum, at least in part, 
secondary to altered Fe metabolism. It is noteworthy that the increment in Fe levels approached 
20–35 %, while Mn levels increased 400–650 % at 10 and 20 mg Mn/kg, respectively. 
Moreover, significant elevation in F2-IsoPs concentration was observed with all the Mn doses, 
including the 5 mg Mn/kg in which the striatal Fe level remained indistinguishable from controls 
(Fig. 1a). In contrast, other studies reported decreased brain Fe levels in animals exposed to 
excessive Mn (Fitsanakis et al. 2010; Garcia et al. 2006; Guilarte and Chen 2007; Guilarte et al. 
2006; Hansen et al. 2009) paralleled by increased transferrin (Tf) plasma levels, and divalent 
metal 1 transporter (DMT-1) and Tf receptor (TfR) expression (Garcia et al. 2006). While these 
changes may possibly explain the increased levels of Fe observed in our study, additional studies 
will be required to determine expression and/or activity of these transporters in the treatment 
protocol described herein. 
According to our previous study (Cordova et al. 2012), Mn exposure led to increased striatal 
oxidative stress, characterized by significant elevation in F2-IsoPs concentrations (Fig. 4). F2-
IsoPs are prostaglandin-like molecules produced by the free radical-mediated peroxidation of 
arachidonic acid (Milatovic and Aschner 2009), which can be efficiently reduced by antioxidant 
treatment (Milatovic et al. 2011). Several studies have shown oxidative stress to be a major 
mechanism for Mn-induced neurotoxicity in both in vitro and in vivo models (Benedetto et al. 
2009; Gunter et al. 2006; Milatovic et al. 2009; Roth and Garrick 2003; Tamm et al. 2008; Zhang 
et al. 2008). Mn-induced ROS generation (Avila et al. 2008; Park and Park 2010; Roth 2009) is 
triggered by dysfunctional mitochondria, resulting in both apoptotic and necrotic cell death (Roth 
and Garrick 2003; Tamm et al. 2008; Yin et al. 2008), triggering the opening of the permeability 
transition pore (Roth 2009; Zhang et al. 2004). Consistent with these observations, we show that 
Mn induced an increase in striatal caspase activity (Fig. 3) and that Trolox™ attenuated the Mn 
(20 mg/kg)-induced increase in F2-IsoPs generation (Fig. 8) and restored caspase activity to 
control levels (Fig. 7). 
In addition to oxidative stress generation and activation of caspases, many classic intracellular 
signaling pathways associated with programmed cell death are altered by Mn treatment in vitro. 
Among them are the activation of MAPKs and Akt (Gonzalez et al. 2008; Hirata et al. 2004; Ito 
et al. 2006; Li et al. 2010; Park and Park 2010; Prabhakaran et al. 2008; Yin et al. 2008). Herein, 
we observed p38MAPK and Akt activation in the striatum of immature rats exposed for 20 days 
to Mn (Fig. 2a, b). Interestingly, co-treatment with Trolox™ led to a significant reduction in 
p38MAPK phosphorylation to the levels indistinguishable from controls. This effect suggests 
that Mn-mediated p38MAPK activation might be occurring via a ROS-dependent mechanism 
(Fig. 6a). Conversely, the activation of Akt by Mn (20 mg/kg; Fig. 2b) appeared independent of 
oxidative stress, since Trolox™ was ineffective in reversing the Mn-dependent Akt activation 
(Fig. 6b). It is noteworthy that Trolox™ itself also increased Akt phosphorylation, consistent 
with the previous studies (Choi et al. 2012; Sun et al. 2012). Although our results point to the 
ability of Mn to activate the Akt pathway (present study; Cordova et al. 2012; McDougall et al. 
2011), the understanding of the mechanism and the toxicological significance of this effect 
remain elusive. Accordingly, it is possible that ROS production-independent mechanisms, such 
as neurotransmitter imbalances, might be involved in the Akt activation in response to Mn. 
Nonetheless, additional studies are necessary to address this possibility. 
DARPP-32 phosphorylation was also altered in response to 20-day Mn exposure (Fig. 2c). 
DARPP-32 is highly expressed in striatal medium spiny neurons, and it is implicated in 
modulation of motor responses in the striatum (Polissidis et al. 2010) by integrating 
dopaminergic and glutamatergic pathways. In this way, D1 receptor activation by dopamine 
stimulates DARPP-32 phosphorylation at Thr-34 (via cAMP/PKA) and thereby converts 
DARPP-32 into a potent inhibitor of protein phosphatase 1 (PP1). Conversely, DARPP-32 is also 
phosphorylated at Thr-75 in response to glutamate (via Cdk5 activation), converting DARPP-32 
to an inhibitor of PKA (Svenningsson et al. 2004). Recently, we demonstrated the modulation of 
DARPP-32 by Mn in a short-term exposure protocol (Cordova et al. 2012), noting increased 
phosphorylation of DARPP-32 at Thr-34 in PN14 rats treated with 5 and 10 mg Mn/kg. Herein, 
we noted a slight decrease in the phosphorylation of DARPP-32-Thr-34 and no changes at Thr-
75 in PN29 rats exposed to 20 mg Mn/kg (Fig. 2c). These differences might potentially reflect 
changes in striatal dopaminergic signaling, which alter the availability of dopamine and/or 
dopamine receptors (Guilarte et al. 2008). 
In addition to the cell signaling alterations, we also noted significant behavioral changes in 
developing rats exposed to Mn (20 mg/kg) for 20 days, characterized by a significant decline in 
motor coordination (Fig. 5). Co-treatment with Mn and Trolox™ significantly improved the 
animals’ performance in the rotarod task (Fig. 9). Mn (20 mg/kg) also decreased the distance and 
speed traveled in the open-field task (Fig. 10), but in this case Trolox™ failed to mitigate the 
Mn-induced effects. Altered movement has been previously shown to be associated with 
increased oxidative stress, mainly in the striatum (de Oliveira et al. 2007). Furthermore, an in 
vivo study conducted in nonhuman primates showed a direct correlation between the levels of 
Mn in the caudate nucleus, putamen and globus pallidus, and the severity of the behavioral 
deficits (Schneider et al. 2009). Thus, the significant accumulation of Mn in the striatum, the 
generation of oxidative stress, apoptotic cell death and disturbed cell signaling in response to Mn 
exposure might directly or indirectly trigger these behavioral deficits. However, this possibility 
needs to be confirmed in future studies. 
Mn has a relatively long half-life in the CNS, consistent with a slow elimination rate (Morello et 
al. 2008). Exposure of developing individuals to Mn levels that exceed the homeostatic capacity 
may result in an overload condition, with increased risk for neurodegenerative diseases, such as 
Parkinson’s disease at later life stages (Lucchini and Zimmerman 2009). Our study shows that 
developmental exposure to Mn induced oxidative stress, perturbed cell signaling pathways and 
triggered behavioral dysfunction. Moreover, we showed that Trolox™, a potent antioxidant, 
significantly attenuated the Mn-induced ROS generation. Therefore, future studies could be 
profitably directed to determine the therapeutic efficacy of this agent in reducing Mn-induced 
neurodevelopmental effects. 
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